#United States #AI Technology #Phoenix #BioLab Holdings #cureVision

BioLab Holdings Announces Strategic Investment in AI Wound Care Technology

On September 4, 2025, BioLab Holdings, Inc., a Phoenix-based leader in the medical manufacturing sector known for its specialized wound care products, declared an exciting partnership with cureVision, a German health-tech innovator. This collaboration aims to enhance the landscape of wound assessment, utilizing cutting-edge artificial intelligence and optical sensor technologies.

cureVision has developed a groundbreaking solution that significantly streamlines wound assessment processes, empowering healthcare professionals to perform rapid and contact-free evaluations that take less than two minutes. This technology is already certified under the rigorous European Medical Device Regulation (MDR), which further validates its effectiveness and reliability. By simplifying the complex steps of measurement, analysis, and documentation, cureVision's system minimizes the manual workload of clinicians, ensuring that they can concentrate more on patient care rather than administrative tasks.

Jaime Leija, President of BioLab, expressed enthusiasm about the partnership, stating, “This collaboration with cureVision represents our commitment to advancing clinically differentiated technologies. Our shared goal is to create a more effective continuum of care.” BioLab is set to support cureVision’s entry into the U.S. market, making this revolutionary solution accessible to a wider audience in the healthcare sector.

The potential impact of introducing cureVision’s technology to the American healthcare landscape is immense. Richard Fobo, CEO of cureVision, emphasized the importance of utilizing advanced technologies in patient care. “cureVision is putting advanced technologies to work, allowing providers to focus on what matters most—the patient,” he noted, highlighting the synergy between the companies in improving healthcare outcomes.

Additionally, Dr. Carlos Encinas, BioLab's Chief Science Officer, acknowledged the promising future of wound care workflows as a result of this partnership: “By combining their advanced imaging capabilities with our distribution network, we are accelerating a smarter, more efficient approach to wound management.” BioLab’s investment will aid cureVision in navigating the regulatory landscape and developing reimbursement strategies in the U.S. Armed with BioLab's extensive national distribution network, cureVision will benefit from seamless commercialization support.

Dr. Marshall Medley, BioLab's Chief Medical Officer, also praised the collaboration, noting, “cureVision’s technology marks a significant advancement in wound care diagnostics.” He explained that the ability to conduct fast point-of-care assessments will enhance the accuracy of wound documentation and ultimately improve treatment decisions made by clinicians.

Through this partnership, cureVision will gain insights directly from U.S. customers—including distributors, healthcare providers, and patients—allowing for a tailored approach to market entry. BioLab's medical advisory group, led by Dr. Medley, will provide strategic guidance to ensure the technology meets the high standards required in the competitive healthcare environment.

Under the combined tagline “Two Missions, One Vision,” both BioLab and cureVision are dedicated to delivering superior wound care solutions aimed at benefiting patients, providers, and payers alike. As a proud innovator in the wound care sector, BioLab Holdings remains committed to developing safe, high-quality products designed to optimize healing and improve patient performance through ongoing innovation.

BioLab's portfolio includes a range of products such as Membrane Wrap - Lite™, Membrane Wrap™, and others—all derived from human tissue allografts to enhance wound protection and healing outcomes. Meanwhile, cureVision continues to lead the way in improving wound care through its advanced artificial intelligence technologies.

In an era where healthcare continues to evolve rapidly, this strategic investment between BioLab and cureVision embodies the forward-thinking approach necessary to meet the dynamic needs in wound care. The partnership is anticipated to set new benchmarks for efficiency and effectiveness in wound management, paving the way for better practices and enhanced patient outcomes across the board.